Emily Eng

How Kay Deguchi Leads PHC Holdings Corporation Through Challenging Times Kyoko “Kay” Deguchi hit the ground running. Appointed as Chief Executive Officer of healthcare solutions company PHC Holdings in April 2024, it marked a pivotal turning point for the Tokyo-based company, which faced what she called “a challenging time” in its growth journey. It’s a challenge she’d been preparing for more than two decades. She earned a law degree from the University of Tokyo, an MBA from Harvard Business School, and brought experience from stints at Bain & Company, and later held senior roles at GE Plastics, Janssen Pharmaceuticals, Stryker Japan, and AbbVie Japan. When PHC announced her new role in early 2024, outgoing CEO Shoji Miyazaki knew she was ready, saying he was “confident [she] will lead the future growth of PHC Group.” In her first year, Deguchi quickly reshaped PHC’s strategic direction. Under her leadership, PHC formally adopted a new vision in 2024: “Be a leader in precision technology that powers the future of healthcare.” Naturally, it wasn’t just talk. In March 2025, PHC announced that one of its subsidiaries had developed a new production technology with Cyfuse Biomedical K.K. to manufacture three-dimensional cell products more reliably. By combining Cyfuse’s bio-3D printing with PHC’s LiCellGrow cell expansion system, they enabled real-time monitoring of metabolic activity in 3D cell cultures—a longstanding technical challenge. Deguchi’s approach also emphasizes talent and culture. Within months of taking the job, she carried out a global roundtable tour involving over 500 employees across PHC’s subsidiaries to promote inclusion and accelerate transformation, according to industry coverage. As the company continues to evolve under her stewardship, Deguchi appears committed to building a globally integrated, innovation-driven company—running through these challenging times like a sprinter through the finish line who immediately lines back up, ready to run again.

151

HealthCo Healthcare & Wellness REIT (ASX: HCW) today released its results for the full year ended 30 June 2026. HealthCo’s focus during the period was advancing the resolution of the Healthscope situation, while continuing to deliver strong operational performance and disciplined balance sheet management across the portfolio. Key financial and portfolio highlights include:  1. 100% of rent collected & 99% occupancy 2. FY26 FFO of 4.0cpu ($21.9m)  3. +4.1% like-for-like NOI growth Healthscope Update: 1. 100% of rent has been received up to and including August 2026 2. Continuity of healthcare services has been maintained across all hospitals 3. The transition of the Mount Private Hospital is on track, with the new lease commencing in October 2026 4. Terms have been agreed with experienced Australian private hospital operators for the remaining 10 hospitals owned by HCW and the Unlisted Healthcare & Life Sciences Fund (UHF), subject to Receiver and Healthscope lender approvals For additional information, please refer to the FY26 financial results presentation below or visit https://bit.ly/4xJF6bw Disclaimer: Past performance should not be taken as an indicator of future performance. This general information does not take into account your investment objectives, financial situation or needs. See https://bit.ly/4jSO5kL for more information on HealthCo Healthcare & Wellness REIT.

51

🌏 MedTech in Asia-Pacific is booming! At #MedTechWorldSingapore2025, Peter Liddell, APAC Healthcare & Life Sciences Sector Leader, KPMG Singapore, shared why the region is a $140B opportunity for investors and innovators alike. From aging populations to almost 1 billion Southeast Asians lacking basic healthcare access, intelligent healthcare devices and MedTech innovation are emerging as the solution to region-wide healthcare challenges costing governments $250B annually. 💡 Key insight: MedTech spending in Asia-Pacific is set to outpace global markets, creating massive potential for startups, investors, and healthcare providers. 🎥 Watch Peter Liddell break down the trends, investments, and opportunities shaping the future of healthcare in Asia-Pacific. #MedTechWorld #MedTechAsia #HealthcareInnovation #InvestInMedTech #AsiaPacificHealthcare

10